Human HLA-A*24:02&B2M&MAGE-A3 (IMPKAGLLI) Monomer Protein

vaccine immunotherapy in patients with PCa.






| Description | |
|-------------------------|---|
| Source | Recombinant Human MAGE-A3(HLA-A*24:02) Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus. |
| | It contains Gly25-Thr305(HLA-A*24:02), Ile21-Met119(B2M) and IMPKAGLLI peptide. |
| Accession | AAA59600.1(HLA-A*24:02)&P61769(B2M)&IMPKAGLLI |
| Molecular Weight | The protein has a predicted MW of 50.20 kDa. Due to glycosylation, the protein migrates to 55-60 kDa based on Bis-Tris PAGE result. |
| Endotoxin | Less than 1 EU per μg by the LAL method. |
| Purity | > 95% as determined by Bis-Tris PAGE |
| | > 95% as determined by HPLC |
| Formulation and Storage | |
| Formulation | Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
| Reconstitution | Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions. |
| Storage | -20 to -80°C for 12 months as supplied from date of receipt80°C for 3 months after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |
| Background | |
| | Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. MAGE-A3 can be considered as a predictor for poor prognosis and an option for |

Assay Data

Bis-Tris PAGE



Human HLA-A*24:02&B2M&MAGE-A3 (IMPKAGLLI) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


SEC-HPLC

Human HLA-A*24:02&B2M&MAGE-A3 (IMPKAGLLI) Monomer Protein

Cat. No. MHC-HM434



Assay Data



The purity of Human HLA-A*24:02&B2M&MAGE-A3 (IMPKAGLLI) Monomer is greater than 95% as determined by SEC-HPLC.